The production facility being established will become a unique component of the innovations infrastructure of the Novosibirsk region. Project implementation will accelerate commercialization of the perspective developments by the research institute’s scientists in the area of innovative pharmaceuticals and will allow certain social and economic constraints to be resolved.
Provided full workload of the production unit, it will be able to produce about 50 kg of pharmaceuticals per year. Such production volume will allow the enterprise fully to meet the Russian demand. The products’ compliance with the GMP standards will allow the company to enter the foreign markets (Europe, Japan, Ukraine, and USA).
Due to funding of target programs (in the framework of the Pharma 2020 strategy and the Rosnano projects), the number of innovative biopharmaceuticals will grow. However, the country lacks specialized infrastructure facilities, which would contribute to their commercialization. The pilot biopharmaceutical center is a strategically important infrastructure project, which is supposed to ensure implementation of a new innovative economy in the area of the Russian health care system.
Detailed information can be found at: http://icnso.ru/en/projects/establishing_a_pilot_center_for_bioinformatics.html
Другие проекты кластера